title: Rituximab therapy for severe refractory chronic Henoch-Schönlein purpura.
abstract: To report on the efficacy of rituximab (RTX) therapy in standard treatment-refractory, chronic Henoch-Schönlein purpura, a retrospective chart review of 3 pediatric patients treated with RTX for severe refractory chronic Henoch-Schönlein purpura was performed. All 3 patients responded to 1 or 2 courses of RTX without serious adverse events.
authors: University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
authors: Katherine J
authors: KJ
authors: Donnithorne
authors: T Prescott
authors: TP
authors: Atkinson
authors: Claas H
authors: CH
authors: Hinze
authors: Janaina B
authors: JB
authors: Nogueira
authors: Shehzad A
authors: SA
authors: Saeed
authors: David J
authors: DJ
authors: Askenazi
authors: Timothy
authors: T
authors: Beukelman
authors: Randy Q
authors: RQ
authors: Cron
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D002648:Child; D004351:Drug Resistance; D005260:Female; D006801:Humans; D011695:IgA Vasculitis / Q000188:drug therapy*; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D012189:Retrospective Studies; D000069283:Rituximab; D012720:Severity of Illness Index
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab